VAXCYTE INC (PCVX) Fundamental Analysis & Valuation

NASDAQ:PCVX • US92243G1085

60.765 USD
+0.95 (+1.58%)
Last: Mar 4, 2026, 12:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PCVX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PCVX. PCVX was compared to 520 industry peers in the Biotechnology industry. PCVX has a great financial health rating, but its profitability evaluates not so good. PCVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. PCVX Profitability Analysis

1.1 Basic Checks

  • PCVX had negative earnings in the past year.
  • PCVX had a negative operating cash flow in the past year.
  • In the past 5 years PCVX always reported negative net income.
  • PCVX had a negative operating cash flow in each of the past 5 years.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M -800M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -25.53%, PCVX is in the better half of the industry, outperforming 70.19% of the companies in the same industry.
  • The Return On Equity of PCVX (-28.55%) is better than 76.15% of its industry peers.
Industry RankSector Rank
ROA -25.53%
ROE -28.55%
ROIC N/A
ROA(3y)-22.44%
ROA(5y)-24.08%
ROE(3y)-25%
ROE(5y)-26.74%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • PCVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PCVX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, PCVX has more shares outstanding
  • Compared to 5 years ago, PCVX has more shares outstanding
  • There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 14.83 indicates that PCVX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 14.83, PCVX belongs to the best of the industry, outperforming 86.73% of the companies in the same industry.
  • There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.83
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 7.91 indicates that PCVX has no problem at all paying its short term obligations.
  • The Current ratio of PCVX (7.91) is better than 73.08% of its industry peers.
  • A Quick Ratio of 7.91 indicates that PCVX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.91, PCVX is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.91
Quick Ratio 7.91
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PCVX Growth Analysis

3.1 Past

  • PCVX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.13%.
EPS 1Y (TTM)-48.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PCVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.46% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.53%
EPS Next 2Y-10.48%
EPS Next 3Y-0.12%
EPS Next 5Y23.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2026 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. PCVX Valuation Analysis

4.1 Price/Earnings Ratio

  • PCVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.48%
EPS Next 3Y-0.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCVX Dividend Analysis

5.1 Amount

  • PCVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCVX Fundamentals: All Metrics, Ratios and Statistics

VAXCYTE INC

NASDAQ:PCVX (3/4/2026, 12:53:42 PM)

60.765

+0.95 (+1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners110.17%
Inst Owner Change-0.24%
Ins Owners0.65%
Ins Owner Change-24.21%
Market Cap8.75B
Revenue(TTM)N/A
Net Income(TTM)-766.63M
Analysts85.88
Price Target102.23 (68.24%)
Short Float %9.62%
Short Ratio9.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.49%
Min EPS beat(2)-20.53%
Max EPS beat(2)-16.44%
EPS beat(4)1
Avg EPS beat(4)-9.08%
Min EPS beat(4)-20.53%
Max EPS beat(4)2.74%
EPS beat(8)4
Avg EPS beat(8)3.01%
EPS beat(12)6
Avg EPS beat(12)-2.01%
EPS beat(16)6
Avg EPS beat(16)-3.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.2%
EPS NY rev (1m)-3.54%
EPS NY rev (3m)-8.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)11.11%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.26
P/tB 3.26
EV/EBITDA N/A
EPS(TTM)-5.62
EYN/A
EPS(NY)-7.06
Fwd EYN/A
FCF(TTM)-4.95
FCFYN/A
OCF(TTM)-4.56
OCFYN/A
SpS0
BVpS18.66
TBVpS18.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.53%
ROE -28.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.44%
ROA(5y)-24.08%
ROE(3y)-25%
ROE(5y)-26.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 347.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.91
Quick Ratio 7.91
Altman-Z 14.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1399.92%
Cap/Depr(5y)958.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.51%
EPS Next Y-25.53%
EPS Next 2Y-10.48%
EPS Next 3Y-0.12%
EPS Next 5Y23.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.84%
OCF growth 3YN/A
OCF growth 5YN/A

VAXCYTE INC / PCVX FAQ

Can you provide the ChartMill fundamental rating for VAXCYTE INC?

ChartMill assigns a fundamental rating of 3 / 10 to PCVX.


What is the valuation status for PCVX stock?

ChartMill assigns a valuation rating of 0 / 10 to VAXCYTE INC (PCVX). This can be considered as Overvalued.


Can you provide the profitability details for VAXCYTE INC?

VAXCYTE INC (PCVX) has a profitability rating of 1 / 10.


Can you provide the financial health for PCVX stock?

The financial health rating of VAXCYTE INC (PCVX) is 8 / 10.


What is the expected EPS growth for VAXCYTE INC (PCVX) stock?

The Earnings per Share (EPS) of VAXCYTE INC (PCVX) is expected to decline by -25.53% in the next year.